Barrier antifungal therapy flunks Phase III trial

Barrier Therapeutics antifungal drug Hyphanox failed to demonstrate that it was at least as effective as Pfizer's Diflucan for treating yeast infections in a Phase III trial. "The outcome of the study is disappointing. While we were able to demonstrate that clinical efficacy was not inferior to that of fluconazole, the therapeutic cure, which also includes the mycological assessment, did not meet the non-inferiority criteria," said Dr. Geert Cauwenbergh, chairman and CEO of Princeton, New Jersey-based Barrier. "We will continue to analyze the massive amount of data to determine next steps for this indication."

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial. 

The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.